期刊
JOURNAL OF CONTROLLED RELEASE
卷 268, 期 -, 页码 305-313出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2017.08.035
关键词
Diabetes; Peptide nanoparticle; Oral delivery; Hypoglycemia; Anti-obesity
资金
- National Leading Research Laboratory through the National Research Foundation of Korea (NRF) - Korean Government [NRF-2015R1A2A1A05001832]
- National Research Foundation of Korea (NRF) - Korea Government [2015R1D1A1A09060567, NRF-2014R1A2A2A03004802]
- Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C2099]
- National Research Foundation of Korea [2015R1D1A1A09060567] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据